Professor Nick Maynard is the kind of surgeon that everyone hopes to see before an operation. Talking with me on video call, he shows a warming enthusiasm and friendliness that would reassure any patient, or student interviewer. This gentle humility makes the horror of the stories he has to tell, those from working in hospitals in Gaza, all the more jarring, and impossible to forget. 

Professor Maynard studied Medicine at Exeter College, Oxford, and works now as a consultant gastrointestinal surgeon at Oxford University Hospitals alongside private practice. As a leading specialist in his field, Dr Maynard can expect to get attention from his peers in medical practice and research. It’s his work in Gaza that has given him global reach.

Palestine and Oxford have featured together in Maynard’s life for decades. He first visited the West Bank in 2006, knowing, of his own admission, very little about the history of Palestine, only “what I’d learned in school”. Visiting the streets of Old Jerusalem, Maynard described being “inspired by the people I met, by the beauty of the land”. 

Originally visiting Palestine yearly to teach medical students, he first went to Gaza in 2010, and “never looked back”, taking teams of doctors from Oxford. His trips focused on developing his specialism in oesophageal and stomach surgery, and he began to get involved with Medical Action for Palestinians (MAP), a UK charity of which Maynard is now the chairman.

Even before the Hamas attacks on Israel on 7th October 2023 and the resulting Israeli military action, Maynard says those living in Gaza were “effectively in prison”, with bombings a “way of life” for Gazans. “Even prior to October 7th, Gaza has been a very challenging place to visit, to live in, to provide healthcare. Its economy has been almost completely destroyed for years. I’ve never, ever been to Gaza in all those years without witnessing, every single trip, aerial attacks from the Israeli military.”

Nonetheless, Maynard says that “nothing could have prepared us for the horrors we saw” when returning to the territory on Boxing Day 2023. His gaze strays from the camera slightly as he described his approach to Gaza from Egypt: “We’d stayed a few miles short of Rafah the night before, and it was a beautiful, sunny day, not a cloud in the sky. And as we approached Gaza, you could see this low-lying cloud over the whole of southern Gaza, smoke from the incessant bombing. And you could smell it from about a mile or two away. You could smell Gaza.” 

Graphic videos on social media and messages from Palestinian friends on the ground could do nothing to prepare him for “the sheer devastation of the bombing, the thousands upon thousands upon thousands of displaced refugees…for the volume of injuries”. The hospitals were “completely packed”, not just with the injured, but also with their families and others displaced from across Gaza, with their homes completely destroyed in Israeli bombardments.

Professor Maynard has been to Gaza on three occasions since 7th October 2023. He has been very successful at getting media attention to raise awareness of the plight of the Palestinians – appearing on the BBC, Channel 4, CNN, and contributing to respected newspapers from across the political spectrum, from the Guardian to the Daily Telegraph. Discussing one of the most divisive issues of our time, it’s the precision of a surgeon’s instruction that makes his advocacy particularly effective. His careful analysis of evidence reaches conclusions that cannot be dismissed easily by the Israeli government as misinformation or pro-Hamas propaganda. His diagnosis is clear: Israel’s actions in Gaza constitute a genocide – “and I want you to use that word in this article”, he insists.  

Still, his channelled anger is palpable when I ask him about the accusations of war crimes levelled at the Israeli Defense Forces (IDF) by organisations such as Amnesty International, Médecins Sans Frontières, and a United Nations Commission on Inquiry. He provides copious testimony, as he is accustomed to doing in interviews across mainstream media outlets: “Friends of mine have been abducted, detained, tortured to death,” he says, emphasising every word. Others who survived torture met him after their release, and gave “very detailed audio and video testimonies of how they’ve been tortured, all of which I’ve submitted to the international courts”. 

I ask Maynard explicitly about accusations made by him and countless others, that Israel is deliberately targeting hospitals and medical workers in Gaza. He explained how, when working at Al-Aqsa Hospital in July 2024, his team would communicate every day with the Israeli authorities through COGAT, the liaison service of the IDF, to confirm that it was safe to work in the hospital.  Maynard says they were told: “You will be protected. There will be no military activity.” 

“They lied to us, because clearly they did attack the hospitals. They attacked the house we were in. I’ve witnessed with my own eyes the hospitals being targeted. I’ve witnessed friends being killed. I’ve seen the clearest evidence of the deliberate targeting of hospitals and healthcare workers. These are all war crimes.” 

Maynard has been asked the same thing by journalists on dozens of occasions now. His frustration is most clearly directed at the “utterly ludicrous” defences given by spokespeople for, and supporters of, the Israeli government, who he says are “given substantial airtime by the BBC and other awful media outlets”. The Israeli Government, Dr Maynard claims, has never given any “verifiable or remotely credible evidence” to support their defences to charges of war crimes, or to justify attacks on medical infrastructure. “If it wasn’t so depressing,” Maynard continues, “it’d be laughable”.

Israeli authorities have repeatedly justified attacks on medical infrastructure by claiming such buildings have been used by Hamas as command centres, or to store weaponry. “Hamas may be in the tunnels. I’ve no idea, I’ve never been in them. I don’t know what’s going on in the peripheral outbuildings, 100 metres away from the main clinical buildings, they may be based there”, he acknowledges. However, Maynard is unequivocal that there was “not one shred of evidence” that Hamas were operating in clinical areas of the hospital grounds. “They’re not bombing the outbuildings, they’re bombing the clinical areas, and that is where there are patients, that is where there are healthcare workers, that is where there are medical students. These are the people who are being killed by their bombs.”

Maynard says that the medical students whose workplaces are being targeted are “utterly remarkable”. Working in Al-Nasser hospital in southern Gaza, he was surrounded by students “in the middle of a war zone, desperate to learn and succeeding in learning”. With the medical schools destroyed by bombing, lectures and exams have been held in makeshift tents amid a backdrop of bombing. Maynard recounts invigilating one clinical exam for fourth-year medical students, all living in tents with no running water or electricity: “I think there must be about 20 or 30 students, they all turned up… all of them in freshly pressed, beautifully clean white coats. I was just gobsmacked.”

It’s a far cry from the modern medical training facilities of the Oxford Clinical School, which Maynard is keen to pay tribute to for facilitating the rescue of two Gazan medical students to continue their education. These two students, however, are from a total of only four Gazan medical students who made it to the UK following 7th October 2023, a number which Maynard describes as “shameful”. 

Maynard came back from Gaza most recently in July 2025, after a trip where he sustained injuries to his head whilst working in Al-Nasser Hospital. After giving interviews from the hospital in Gaza, including to the BBC with a bandage still wrapped around his head, he has since devoted his free time back in the UK to activism and advocacy. At the same time, he has returned to his full-time job as a consultant surgeon at Oxford University Hospitals. Returning to normality and the “day job” in Oxford, he says it was impossible to know what to expect after “the profound impact … [of] dealing with atrocities”. 

“I had children, patients of mine die under my hands because we couldn’t stop the bleeding from the gunshot wounds”, Maynard recounts. He tells the story of eleven-year-old Habiba, who was left with a severe oesophageal injury, after a bomb explosion. “I spent the whole night operating on her, reconstructing her oesophagus, but we couldn’t feed her. We had no nutrition to come in, and she died predominantly of malnutrition a few weeks later, despite the fact the surgery had itself been very successful”. Moments like those, he says, “you never forget…they’re imprinted on your memory”. 

The return home came with profound relief and “enormous guilt”, as Maynard’s Palestinian friends and fellow surgeons remained trapped in Gaza. However, for Maynard, it’s after “saying goodbye to friends who you know you may not see again…to patients who may not survive, you feel the most profound anger” towards the West’s politicians and mainstream media outlets. Guilt and anger have left him with an “unbelievable, powerful urge…to tell everyone what I’ve seen, because they’re not hearing it from the media…the clear genocide…the war crimes, the ethnic cleansing”. 

And so Maynard continues to give interviews like this one. It’s a “double-edged sword”, he tells me, because “when you recount all these stories, it brings back all the horrible memories. But the overall benefit is this compulsion to share”.  

When you leave Gaza, he says, “you feel inadequate again. You want to be back out there”.  Despite the “emotional turmoil” he feels after visiting the territory, he is clear that the experience has been “life-changing and life-enhancing”. Spending time in Gaza has been “a wonderful privilege, and the last two years have in many ways changed my life”. As he speaks, I look towards the colourful woven map of Palestine hanging on the door behind him.

He says he’s “desperate” to return, but the chance to volunteer in Gaza again looks highly unlikely with his raised public profile of pro-Palestinian advocacy: “People like me, who have spoken out a lot, are not being allowed in” by the IDF, who continue to control all access to Gaza by medical staff, as well as aid workers, aid delivery drivers and journalists. A law introduced in January now forces all aid organisations to register with the Israeli government and submit the personal details of all their staff to the Israeli authorities, leaving 37 non-compliant aid organisations facing bans from accessing the territory, including Médecins Sans Frontières (MSF).

With it looking unlikely that Professor Maynard will be able to work on the ground in Gaza any time soon, his activism in the UK takes on a heightened importance. He laments how global pro-Palestinian activism has “diminished” in recent months. “The marching has reduced, the vigils have stopped…the media isn’t reporting anything about Gaza.” He blames the reduced coverage on public understanding of the official ceasefire in Gaza, dismissed as “propaganda” by Maynard. “There’s not a ceasefire. There’s been a reduction in the violence, but there are still Gazans being killed by the Israelis every single day. The need for advocacy and activism is as great as ever”. 

Making small talk before and after the interview, Maynard appeared immensely calm, composed, affable. It makes his anger towards the UK Government and the University of Oxford all the more profound: “Oxford University is doing nothing like enough… the University authorities, by and large, have been silent, and that’s unacceptable.” 

For Maynard, the “woeful silence” of our political institutions amounts to complicity, whilst the UK Government has been outright dishonest. “Don’t believe the government when they say they’re an arms embargo. There’s not.” He accuses the RAF of “providing military intelligence” for Israel through reconnaissance flights over Gaza, condemned continued UK trade with Israel, and highlighted recent cooperation between the UK Government and Palantir, the US data analytics company, which was given a £330 million contract with the NHS in 2023, whom Maynard accuses of having “strong links to the Israeli military”. 

Maynard’s testimony can appear extreme, even desperate, to a sceptical observer. The scale of the horror, the strength of the anger around Gaza, makes every attempt to describe what is happening there immensely polarising. Yet hearing him speak, Maynard’s anger does not come across as that of a partisan, but rather the quiet fury of an expert in their field, giving evidence on one of the greatest atrocities of our time, and feeling ignored by those he sees as complicit. 

So, what students at Oxford University could do to make a difference? For Maynard, the answer is obvious. Students should do “what students have been the best at doing for decades: standing up for those who need support, standing up for the underprivileged, standing up for the victims of genocide.”

Anyone who describes reviewing a student play as a burden simply hasn’t watched a good play for some time. A free seat to watch young actors, directors, cast, and crew put all their effort into a production with minimal funding and frills is always an incredible experience. Ulster American is one such production. In the limited space of the Burton Taylor studio, set amazingly by Naomi Flexman and well lit according to the conditions of the play by Gabrielle Panova, the creative and personal struggle between the trio within the director’s apartment is brought to life. 

Whilst David Ireland is a fantastic playwright, with his work drawing such names as Woody Harrelson, Andy Serkis, and Matthew Broderick, the play itself is not fantastically well known, and so directors Kate Burke and Robyn Hayward were confronted with a challenge when producing this black comedy. How to communicate to the audience that the entire play shouldn’t be watched in stony silence, but that its seriousness should also be grasped? The directors, producer Frankie Maino, and welfare officer Madeleine Evans faced an almost impossible challenge, particularly given the sensitive material the play touches on. 

But it is a challenge they have pulled off adeptly, helped by a fantastic cast. With Aaron Gelkoff playing Jay Conway, an American actor almost stereotypically self-centred and shallow, Rohan Joshi as Leigh Carver, the anxious-to-please and superficially sensitive director, the play’s opening thirty minutes were well secured. Gelkoff gave an unforgettable performance that never fell into cliché, even as he played the sort of publicly quasi-intellectual American actor most people can imagine – think Brad Pitt. Joshi gave what I believe to be the finest performance of the night, acting as the cantilever of the play, a director increasingly desperately attempting to keep his production aloft. Conway lauded over Carver with skin-deep soul-searching and quizzical observations that Carver, in his desire to avoid any obstructions to his play, accepts, only raising a swiftly muted challenge when Conway describes a particular debauched and morally bankrupt thought.

A decent way into the play, the arrival of Caeli Colgan as Ruth Davenport, the playwright, upsets the unchallenged dynamic that had prevailed thus far. Davenport, as the eponymous’ play’s auteur, engages with the themes the audience might expect as a product of Ireland. She is brilliant, challenging Conway where Carver had been willing to let issues slide – after her brief awe at his celebrity wanes, of course. Arriving following a car crash with her mother, Davenport’s family looms large over the play, as her own identity as a Protestant Unionist rubs both the quintessential Guardian-reading upper middle class liberal Carver, and the self-righteous Conway, the wrong way. Carver fundamentally fails to grasp the basis for unionist identity, whilst Conway’s idiocy and lack of interest in the play itself – communicated with repetitive, deliberate contradictions by Gelkoff – leads this supposedly proud Irish American to express horror at the fact that, rather than being written by an Irish Catholic, ‘the play was written by a Unionist Protestant Brit.

The energy of the play doesn’t abate once the trio assemble, and the comic elements are used fantastically – it, unlike some black comedies, never fails to elicit laughs from the audience, even as the play thundered towards its dramatic conclusion. But there was something left on the table as the audience stood and applauded and began to file out.  For a play that pertained to be about Irishness and the intricacies of Northern Ireland, juxtaposed with those of America, little examination of either appeared for long. That is partly Ryan Ireland’s sin, but I think that the directors could have been bolder in how they approached his work. Casting someone of colour, for example, in the role of the director – which is not a bash at Joshi, who plays the flawed conciliator to a tee – would have lent a layer of intricacy to the discussion on the use of the N word at the start, and race throughout, that was absent. Having two women in the play, rather than one woman against two men, would have greatly changed the power dynamics regarding discussions of Britishness, Irishness, and its relation to the blunt brutality of the American actor’s wishes; again, this is a sin of Ireland’s, not the cast or crew. The actors are fantastic, and are reliable fixtures of the OUDS circuit that improve with every performance.

Ulster American’s great performances and direction have, however, left its contentious script unchallenged. The ending of the play captures this well. However, whilst it is in line with a black comedy to have Conway and Carver claim credit for Davenport’s success, whilst lumping her with a gendered accusation of mental health issues, this fails to deliver on the promise raised earlier in the play. Davenport – again, played fantastically by Caeli Cogan – is clearly Ireland’s favourite, but she, like Conway, is a character that never reaches the depths of her own morality.

Joshi’s Carver steals the limelight in large part because he reaches beyond the bounds of Ireland’s limits and lends depth and intricacy to the character. He appreciates the experimental element of student theatre, his character attempting to ensure the play’s survival, his own success and conception of himself as a liberal and friend to Davenport. The high drama at the end of the play, featuring an addition not part of the original script, is effective, but the addition is unnecessary. It undermines the nuances to Conway’s character and hamfists what had been a subtle but palpable inequality of power running throughout the play, and serves as a fine allegory for the production itself.

It is superbly acted, fantastically staged and lit, and the production of the play is star-quality. But a failure of directorial ambition, not in producing a poorly directed play but in failing to challenge, or meaningfully amend, Ulster American, precludes it from being a truly great play.

The University’s Oxford Vaccine Group (OVG) is leading the development and trialling of a vaccine in response to the recent Ebola outbreak in the Democratic Republic of Congo (DR Congo). 

The team, led by the Head of Vaccine Immunology and the OVG and Pandemic Sciences Institute, Professor Teresa Lambe OBE, is working alongside the University’s Clinical BioManufacturing Facility and the Serum Institute Pvt. Ltd, to research, create, and trial the viral-vector vaccine. Estimates suggest a workable vaccine could be available within two to three months. 

Depending on its performance at animal trials, a World Health Organisation (WHO) spokesperson said it could be “a promising candidate research vaccine” for the Bundibugyo Ebola strain responsible for the outbreak. 

Lambe told Cherwell: “OVG has more than 30 years of experience in the development and testing of vaccines, which allows us, alongside our partners, to pivot and apply our expertise in times of outbreak…The ability to move rapidly in situations like this has been built on many years of vaccine research and close collaboration with our global partners.” 

The May 2026 Bundibugyo Ebola outbreak, originating in the DR Congo, has been rated a “very high” public health risk by the WHO. Though the risk is low internationally, the WHO declared it a Public Health Emergency of International Concern (PHEIC), a status that encourages cross-continent co-operation. At the time of publication, there have been an estimated 220 deaths and 900 cases, with 11 countries understood to be at risk. 

The specific strain of Ebola, Bundibugyo, is rare and has not been seen for over a decade, with the last two outbreaks occurring in 2007 (in Uganda) and 2012 (in the DR Congo). Naturally occurring in animals and fruit bats, the disease spreads among humans through infected bodily fluids, with research suggesting a mortality rate of between 30 – 50%. 

Initial symptoms are similar to the flu, with illness often beginning with a fever and a headache. Symptoms rapidly progress to vomiting, diarrhoea, and, later, internal bleeding and organ failure. At present, there are no approved vaccines for this particular Ebola species. 

Treatment for the virus has been hindered by violent conflict in the DR Congo between the Congolese military and the M23 rebel group, which has displaced a quarter of a million people.

Having previously worked on the Oxford/AstraZeneca COVID-19 vaccine, as well as vaccines for Sudan Ebolavirus and Marburg Virus, the OVG has utilised the same vector platform (ChAdOx1) used in the COVID-19 vaccine, and adapted it to the Bundibugyo Ebola strain. By altering the genetic code, the vector platform can be tailored to different filoviruses.

The vaccine base relies on a common cold virus, typically found amongst chimpanzees. By altering the viral makeup to ensure it is safe for human beings, the virus can travel around the body, delivering information to cells to target and kill the Bundibugypo virus. However, before trials are completed, the scientists involved cannot guarantee that the vaccine will be effective. 

Once the vaccine has been effectively trialled and approved, it will be sent to the Serum Institute of India to be mass-produced. Lambe said in a statement: “Once we get starting [sic] material to them, they can go fast and they can go big”.

Lambe told Cherwell: “Right now, the focus is on generating the data needed to support development, scaling manufacturing with the Serum Institute of India (SII) Pvt. Ltd, and preparing for clinical trials should they become necessary… My hope is that this outbreak can be brought under control quickly and that vaccines are ultimately not needed.”